ANI Partners with Sterling on Generic Drug

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) today announced that it has entered into a fee-for-service development agreement for a generic drug product with Sterling Pharmaceutical Services (“Sterling.”)
As quoted in the press release:

The product will be developed by Sterling and transferred into ANI’s facilities for commercial manufacture and marketing. The current annual market for this product is $60 million dollars, according to IMS Health.

Read the full press release by ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)